ADDvise streamlines organization through new business area structure

28-10-2024   Regulatory press release

To enhance focus and efficiency, ADDvise is restructuring its two existing business areas, Lab and Healthcare, into separate operational units, each led by a dedicated director. This new structure is designed to optimize the organization, establish a clearer strategic focus, and strengthen the foundation for both organic growth and acquisitions. Additionally, the structure facilitates valuable knowledge-sharing across the group.

The Healthcare business area manufactures and supplies a diverse range of advanced medical technology, high-quality consumables, and pharmaceuticals. By combining innovative, proprietary products with established brands essential equipment is offered to both private and public healthcare providers. Fredrik Mella will take on the role of Head of Healthcare.

The Lab business area delivers comprehensive solutions for modern research environments, including laboratory furniture, safety ventilation, climate and clean rooms, and laboratory equipment. The products support global research and development, with a focus on the pharmaceutical industry and life sciences. Johan Seltborg will take on the role of Head of Lab.

“With this restructuring, we are strengthening our decentralized business model, focusing on the individual company. By reducing costs and improving efficiency, we enhance our ability to achieve both organic growth and growth through acquisitions. I am confident that this change will bring greater clarity, long-term value, and strengthen our capacity to achieve our growth strategy," says Staffan Torstensson, CEO of ADDvise.

Following this restructuring, ADDvise's group executive team will include Staffan Torstensson as CEO, Fredrik Mella as Head of Healthcare, Johan Seltborg as Head of Lab, Johan Irwe as interim CFO, and Hanna Myhrman as General Counsel and Head of M&A. Through cost and efficiency measures, annual costs for central functions are expected to decrease by SEK 18 million.

For further information, please contact:
Staffan Torstensson, CEO
+46 70 433 20 19
staffan.torstensson@addvisegroup.se

About ADDvise Group
ADDvise is an international life science group. Operating a decentralised ownership model, we develop and acquire high quality companies within the business areas Lab and Healthcare. The Group comprises more than 20 companies and generates annual revenues of close to SEK 2 billion. ADDvise is listed on Nasdaq First North Premier Growth Market. Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the company's Certified Adviser. More information is available at www.addvisegroup.com.

Latest press releases

Invitation to presentation of interim report October 1 – December 31, 2024

Non-regulatory

ADDvise Group publishes its interim report October 1 – December 31, 2024 on Thursday, February 20, 2025 at 7.45 am (CET). Media, investors and analysts are invited to attend a webcast and teleconference on the same day at 14:00 (CET). CEO, Staffan Torstensson, and Interim CFO, Johan Irwe, will present the report. Webcast If you…

Invitation to presentation of interim report July 1 – September 30, 2024

Non-regulatory

Media, investors and analysts are invited to attend a presentation of the interim report for the period July 1 – September 30, 2024. The presentation will take place on October 24, 2024, at 14:00 (CEST) / 08:00 AM (EST). CEO, Staffan Torstensson, and Interim CFO, Johan Irwe, will present the report in a webcast and…

Invitation to presentation of interim report January 1 – March 31, 2024

Non-regulatory

ADDvise Group’s interim report for the period January 1 – March 31, 2024 will be published on April 18, 2024 at 07:45 (CEST). Investors, analysts, and other stakeholders are invited to a webcast and conference call at 14:00 (CEST) / 08:00 AM (EST) the same day where CEO Rikard Akhtarzand and CFO Oliver Humlen will…